Developing blood tests to predict immunotherapy response in kidney cancer
A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma
This study is testing if blood tests can help predict how well patients with advanced kidney cancer will respond to immunotherapy treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Zhejiang Cancer Hospital Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Hangzhou) |
| Trial ID | NCT05705583 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the use of circulating exosomes as predictive biomarkers for the response to immunotherapy in patients with advanced metastatic renal cell carcinoma (RCC). By collecting blood and urine samples from participants scheduled to receive immune checkpoint inhibitors, researchers hope to identify specific biomarkers that can indicate how well a patient may respond to treatment. The study focuses on patients aged 18 and older who can provide informed consent and excludes those with other active malignancies. The ultimate goal is to enhance personalized treatment strategies for RCC patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with advanced metastatic renal cell carcinoma who are about to start immunotherapy.
Not a fit: Patients with other active invasive malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate predictions of treatment responses, allowing for tailored immunotherapy approaches in kidney cancer patients.
How similar studies have performed: Other studies have explored biomarkers for immunotherapy responses, but the specific use of circulating exosomes in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Advanced Metastatic RCC * Scheduled to initiate an immunocheckpoint inhibitors or in combination with them * Age \>= 18 years * Able to provide informed consent Exclusion Criteria: * Other, unrelated, concomitant active, invasive malignancy
Where this trial is running
Hangzhou
- An Zhao — Hangzhou, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.